Brief: Orexo Sees Positive EBITDA For FY 2025

Orexo AB

06/02/2025 07:16

Feb 6 (Reuters) - Orexo AB  ORX.ST :
    * OUTLOOK 2025: THE BUPRENORPHINE/NALOXONE MARKET WILL GROW 
2-5
PERCENT, BASED ON CURRENT GROWTH TRAJECTORY
    * OUTLOOK 2025: ZUBSOLV NET SALES IN USD IN THE RANGE OF USD
50-55
M
    * OUTLOOK 2025: OPEX EXCLUDING DEPRECIATION AND AMORTIZATION
 IN
THE RANGE OF SEK 460-500 M
    * OUTLOOK 2025: POSITIVE EBITDA FOR THE FY 2025

Source text:  ID:nMFN9WZkYl 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))